Tevogen Bio Holdings (TVGN) Gains from Investment Securities (2022 - 2026)
Tevogen Bio Holdings (TVGN) reported Gains from Investment Securities of $189398.0 for Q1 2026, up 1435.33% on a YoY basis from $12336.0 in Q1 2025, and up 112.03% quarter-over-quarter from -$1.6 million in Q4 2025.
Tevogen Bio Holdings (TVGN) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings has reported Gains from Investment Securities for 5 years, with the latest figure at $189398.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 1435.33% year-over-year to $189398.0; the trailing twelve-month figure through Mar 2026 stood at $189398.0 (up 1435.33% YoY), and the FY2025 full-year result was $189398.0, up 57.83% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $189398.0, up from -$1.6 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $19.3 million in Q2 2024, with the low at -$1.6 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged $1.2 million across 5 years, with a median of $7250.0 in 2023.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities sank 2268.23% — and 2026, when it soared 1435.33%.
- Tevogen Bio Holdings' Gains from Investment Securities stood at -$87000.0 in 2022, then jumped by 108.33% to $7250.0 in 2023, then soared by 901.49% to $72608.0 in 2024, then slumped by 2268.23% to -$1.6 million in 2025, then soared by 112.03% to $189398.0 in 2026.
- The last three Gains from Investment Securities figures came in at $189398.0 (Q1 2026), -$1.6 million (Q4 2025), and -$64959.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Tevogen Bio Holdings | 182.04 Mn | 181.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 189,398.00 |
| Mar 31, 2026 | 189,398.00 |
| Dec 31, 2025 | -1.57 Mn |
| Dec 31, 2025 | -1.57 Mn |
| Sep 30, 2025 | -64,959.00 |
| Sep 30, 2025 | -64,959.00 |
| Jun 30, 2025 | 21,410.00 |
| Jun 30, 2025 | 21,410.00 |
| Mar 31, 2025 | 12,336.00 |
| Mar 31, 2025 | 12,336.00 |
| Dec 31, 2024 | 72,608.00 |
| Dec 31, 2024 | 72,608.00 |
| Sep 30, 2024 | -7,613.00 |
| Sep 30, 2024 | -7,613.00 |
| Jun 30, 2024 | 19.35 Mn |
| Jun 30, 2024 | 19.35 Mn |
| Mar 31, 2024 | 31,973.00 |
| Mar 31, 2024 | 31,973.00 |
| Sep 30, 2023 | 7,250.00 |
| Sep 30, 2023 | 7,250.00 |